Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Clinical outcomes of patients with R/R multiple myeloma listed for treatment with CAR-T therapy

Meera Mohan, MD, MS, FACP, Medical college of Wisconsin, Milwaukee, WI, discusses a study which evaluated the outcomes of patients with relapsed/refractory (R/R) multiple myeloma listed for treatment with commercial CAR-T therapy. Results demonstrated that only one third of patients were able to receive treatment, and Dr Mohan further highlights the importance of improving access to CAR-T therapy, as well as the timing of treatment, to maximize patient outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


GSK: Research Funding; BMS/Celgene: Research Funding; Takeda: Research Funding; Novartis: Research Funding.